448 related articles for article (PubMed ID: 28966266)
1. [Nose-to-Brain Delivery of Peptide Drugs Enhanced by Coadministration of Cell-penetrating Peptides: Therapeutic Potential for Dementia].
Kamei N
Yakugaku Zasshi; 2017; 137(10):1247-1253. PubMed ID: 28966266
[TBL] [Abstract][Full Text] [Related]
2. Effect of an Enhanced Nose-to-Brain Delivery of Insulin on Mild and Progressive Memory Loss in the Senescence-Accelerated Mouse.
Kamei N; Tanaka M; Choi H; Okada N; Ikeda T; Itokazu R; Takeda-Morishita M
Mol Pharm; 2017 Mar; 14(3):916-927. PubMed ID: 28094952
[TBL] [Abstract][Full Text] [Related]
3. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
Kamei N; Takeda-Morishita M
J Control Release; 2015 Jan; 197():105-10. PubMed ID: 25445695
[TBL] [Abstract][Full Text] [Related]
4. Visualization and Quantitative Assessment of the Brain Distribution of Insulin through Nose-to-Brain Delivery Based on the Cell-Penetrating Peptide Noncovalent Strategy.
Kamei N; Shingaki T; Kanayama Y; Tanaka M; Zochi R; Hasegawa K; Watanabe Y; Takeda-Morishita M
Mol Pharm; 2016 Mar; 13(3):1004-11. PubMed ID: 26795701
[TBL] [Abstract][Full Text] [Related]
5. Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction.
Kamei N; Okada N; Ikeda T; Choi H; Fujiwara Y; Okumura H; Takeda-Morishita M
Sci Rep; 2018 Dec; 8(1):17641. PubMed ID: 30518944
[TBL] [Abstract][Full Text] [Related]
6. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats.
Khafagy el-S; Kamei N; Nielsen EJ; Nishio R; Takeda-Morishita M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):736-43. PubMed ID: 24060698
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle transport across in vitro olfactory cell monolayers.
Gartziandia O; Egusquiaguirre SP; Bianco J; Pedraz JL; Igartua M; Hernandez RM; Préat V; Beloqui A
Int J Pharm; 2016 Feb; 499(1-2):81-89. PubMed ID: 26721725
[TBL] [Abstract][Full Text] [Related]
8. Noncovalent Strategy with Cell-Penetrating Peptides to Facilitate the Brain Delivery of Insulin through the Blood-Brain Barrier.
Kamei N; Yamaoka A; Fukuyama Y; Itokazu R; Takeda-Morishita M
Biol Pharm Bull; 2018; 41(4):546-554. PubMed ID: 29607927
[TBL] [Abstract][Full Text] [Related]
9. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
Iwase Y; Kamei N; Khafagy el-S; Miyamoto M; Takeda-Morishita M
Int J Pharm; 2016 Aug; 510(1):304-10. PubMed ID: 27343364
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the Transport Pathways Associated with Enhanced Brain Delivery of Peptide Drugs by Intranasal Coadministration with Penetratin.
Kamei N; Suwabe S; Arime K; Bando H; Murata K; Yamaguchi M; Yokoyama N; Tanaka E; Hashimoto A; Kanazawa T; Ago Y; Takeda-Morishita M
Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834159
[TBL] [Abstract][Full Text] [Related]
11. Insulin Delivery to the Brain via the Nasal Route: Unraveling the Potential for Alzheimer's Disease Therapy.
Wong CYJ; Baldelli A; Hoyos CM; Tietz O; Ong HX; Traini D
Drug Deliv Transl Res; 2024 Jul; 14(7):1776-1793. PubMed ID: 38441832
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive insulin delivery: the great potential of cell-penetrating peptides.
Kamei N; Nielsen EJ; Khafagy el-S; Takeda-Morishita M
Ther Deliv; 2013 Mar; 4(3):315-26. PubMed ID: 23442079
[TBL] [Abstract][Full Text] [Related]
13. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
[TBL] [Abstract][Full Text] [Related]
14. Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin.
Tashima T
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171799
[TBL] [Abstract][Full Text] [Related]
15. Systemic and brain delivery of leptin via intranasal coadministration with cell-penetrating peptides and its therapeutic potential for obesity.
Khafagy ES; Kamei N; Fujiwara Y; Okumura H; Yuasa T; Kato M; Arime K; Nonomura A; Ogino H; Hirano S; Sugano S; Takeda-Morishita M
J Control Release; 2020 Mar; 319():397-406. PubMed ID: 31926192
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of β-amyloid and ibotenic acid into the bilateral hippocampus.
Feng C; Zhang C; Shao X; Liu Q; Qian Y; Feng L; Chen J; Zha Y; Zhang Q; Jiang X
Int J Pharm; 2012 Feb; 423(2):226-34. PubMed ID: 22193058
[TBL] [Abstract][Full Text] [Related]
17. Nanoneurotherapeutics approach intended for direct nose to brain delivery.
Md S; Mustafa G; Baboota S; Ali J
Drug Dev Ind Pharm; 2015; 41(12):1922-34. PubMed ID: 26057769
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2.
Akita T; Kimura R; Akaguma S; Nagai M; Nakao Y; Tsugane M; Suzuki H; Oka JI; Yamashita C
J Control Release; 2021 Jul; 335():575-583. PubMed ID: 34116136
[TBL] [Abstract][Full Text] [Related]
19. From nose to brain: understanding transport capacity and transport rate of drugs.
Wu H; Hu K; Jiang X
Expert Opin Drug Deliv; 2008 Oct; 5(10):1159-68. PubMed ID: 18817519
[TBL] [Abstract][Full Text] [Related]
20. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
Kanazawa T
Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
